Inhibiting tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling

Cancer Research

Volumn 74, Issue 12, 2014, Pages 3294-3305

  Schoumacher, Marie ^a   Hurov, Kristen E ^a   Lehár, Joseph ^a   Yan Neale, Yan ^a   Mishina, Yuji ^a   Sonkin, Dmitriy ^a   Korn, Joshua M ^a   Flemming, Daisy ^a   Jones, Michael D ^a   Antonakos, Brandon ^a   Cooke, Vesselina G ^a   Steiger, Janine ^b   Ledell, Jebediah ^b   Stump, Mark D ^a   Sellers, William R ^a   Danial, Nika N ^c   Shao, Wenlin ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Zalicus Inc   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NVP TNKS656; SELUMETINIB; TANKYRASE INHIBITOR; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL MUTANT; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VOLUME; WNT SIGNALING PATHWAY;

ACETAMIDES; AMINOPYRIDINES; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; FEEDBACK, PHYSIOLOGICAL; FEMALE; HUMANS; MAP KINASE KINASE KINASES; MICE; MICE, NUDE; MORPHOLINES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIMIDINONES; QUINAZOLINES; RAS PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SIGNAL TRANSDUCTION; SULFONAMIDES; TANKYRASES; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903453588     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0138-T     Document Type: Article

References (43)

1. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28. (Pubitemid 44036457)
2. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012;13:411-24.
3. Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 2012;11:923-36.
4. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 2008;90:83-92. (Pubitemid 350216209)
5. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93. (Pubitemid 39128102)
6. Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T, et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011;147:1340-54.
7. Hsiao SJ, Smith S. Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ. J Cell Biol 2009;184:515-26.
8. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
9. Kim MK, Dudognon C, Smith S. Tankyrase 1 regulates centrosome function by controlling CPAP stability. EMBO Rep 2012;13:724-32.
10. Levaot N, Voytyuk O, Dimitriou I, Sircoulomb F, Chandrakumar A, Deckert M, et al. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011;147:1324-39.
11. Ozaki Y, Matsui H, Asou H, Nagamachi A, Aki D, Honda H, et al. Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome maturation. Mol Cell 2012;47:694-706.
12. Cho-Park PF, Steller H. Proteasome regulation by ADP-ribosylation. Cell 2013;153:614-27.
13. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
14. Bregman H, Gunaydin H, Gu Y, Schneider S, Wilson C, DiMauro EF, et al. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J Med Chem 2013;56:1341-5.
15. Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, et al. A novel tankyrase small-molecule inhibitor suppresses apc mutation-driven colorectal tumor growth. Cancer Res 2013;73:3132-44.
16. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wntpathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem 2012;55:1127-36.
17. Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen Z, et al. Identification of NVP-TNKS656 - the use of structure efficiency relationships to generate a highly potent, selective and orally active tankyrase inhibitor. J Med Chem 2013;56:6495-511.
18. Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, et al. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 2011;108:17135-40.
19. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014. (Pubitemid 44835127)
20. Bao R, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS ONE 2012;7:e48670.
21. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010;6:829-36.
22. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 2012;72:4154-64.
23. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, et al. Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
24. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009;27:659-66.
25. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
26. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics 2002;18:1585-92. (Pubitemid 36097723)
27. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011;121:4311-21.
28. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
29. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23:121-8.
30. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we cotarget upstream? Sci Signal 2011;4:pe16.
31. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13:1576-83. (Pubitemid 46450450)
32. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, et al. Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 2012;5:ra3.
33. Jeong WJ, Yoon J, Park JC, Lee SH, Kaduwal S, Kim H, et al. Ras stabilization through aberrant activation of Wnt/beta-catenin signaling promotes intestinal tumorigenesis. Science Signal 2012;5:ra30.
34. Liu J, Pan S, Sun F, Kasibhatla S, Schuller A, Li A, et al. PD08-11: Targeting Porcupine, a critical node for Wnt signalling in cancer. Cancer Res 2011;71(24 Suppl):Abstract nr PD08-11.
35. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
36. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
37. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71.
38. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 2012;72:3228-37.
39. Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell 2011;147:26-31.
40. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell 2011;145:19-24.
41. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283:125-34.
42. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25.
43. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003;278:18811-6. (Pubitemid 36799262)